News from boehringer ingelheim A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 19, 2014, 10:00 ET

Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD

 Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for...

Aug 18, 2014, 17:32 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection)

 The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is...

Aug 14, 2014, 16:35 ET

FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD

 Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory...

Aug 04, 2014, 09:14 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C

  The U.S. Prescribing Information for Jentadueto® (linagliptin and metformin hydrochloride) tablets now includes clinical trial data...

Aug 01, 2014, 23:26 ET
Jardiance (R)  (empagliflozin) 10 mg tablets* *The above image does not reflect the actual size of the tablet (PRNewsFoto/Eli Lilly and Company)

FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA)...

Aug 01, 2014, 08:05 ET

FDA Approves Boehringer Ingelheim's Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

 Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved Striverdi® Respimat® (olodaterol)...

Jul 23, 2014, 14:00 ET

Benefits and Safety of Pradaxa® (dabigatran etexilate mesylate) Repeatedly Confirmed

 Boehringer Ingelheim (BI) wants to set the record straight following misleading statements that the British Medical Journal (BMJ)...

Jul 16, 2014, 11:58 ET

Boehringer Ingelheim's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy...

Jul 08, 2014, 07:38 ET

Boehringer Ingelheim's volasertib Phase II data including new overall survival results in older patients with acute myeloid leukemia published in Blood

 Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in...

Jul 02, 2014, 09:00 ET

U.S. FDA Accepts NDA Filing for Boehringer Ingelheim's Investigational Nintedanib and Grants Priority Review Designation for the Treatment of Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the New Drug Application (NDA) for its investigational compound nintedanib has been...

Jun 27, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union

 The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational...

Jun 27, 2014, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union

The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound...

Jun 26, 2014, 08:02 ET

Boehringer Ingelheim's Investigational Antidote for Pradaxa® (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...

Jun 24, 2014, 11:47 ET

Boehringer Ingelheim Announces Nintedanib Expanded Access Program (EAP) for Patients with Idiopathic Pulmonary Fibrosis

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S. multi-center expanded access...

Jun 20, 2014, 08:00 ET

Boehringer Ingelheim Initiates RE-CIRCUIT™ Trial, Evaluating Pradaxa® (dabigatran etexilate mesylate) in NVAF Patients Undergoing Ablation

 Boehringer Ingelheim announced today the initiation of a new international study of Pradaxa® (dabigatran etexilate mesylate). The...

Jun 19, 2014, 07:59 ET

Study findings show tiotropium Respimat®* well-tolerated and effective in Japanese patients with symptomatic asthma

BURLINGTON, ON, June 19, 2014 /CNW/ - Results from a Phase III 52 week study, show tiotropium (delivered via Respimat®*)5µg, a once-daily...

Jun 17, 2014, 15:53 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the resubmission of a New Drug...

Jun 16, 2014, 11:45 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Type 2 diabetes: Investigational compound empagliflozin as an add-on therapy significantly reduced blood glucose and body weight in two newly presented phase III trials

Two phase III clinical trials studying the efficacy and safety of the investigational compound empagliflozin in type 2 diabetes (T2D) were...

Jun 15, 2014, 15:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials

 Two phase III clinical trials found  the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels...

Jun 14, 2014, 13:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus®

For the first time today, Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the...